Actively Recruiting
Phase 1 Study of DEC003M, an Antibody Drug Conjugate Targeting PSMA for Advanced Prostate Cancer Treatment
Led by Hangzhou DAC Biotechnology Co., Ltd. · Updated on 2026-10-14
110
Participants Needed
7
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying DEC003M, an antibody drug conjugate, in patients with advanced prostate cancer. This Phase 1 open-label trial aims to find the right dose through a dose-escalation phase and then assess early antitumor activity, safety, and how the drug moves through the body in a dose-expansion phase. The study is sponsored by Hangzhou DAC Biotechnology Co., Ltd. Participants receive DEC003M every three weeks in cycles of 21 days. The study includes two phases dose escalation to determine the recommended dose for expansion, followed by dose expansion to evaluate the treatments effects and safety. The treatment is given as a single group without placebo comparison. Participants will be monitored for adverse events from screening through about one year, with assessments for dose-limiting toxicity over three weeks and dose recommendations for up to two years. Researchers will also measure tumor response, PSA changes, progression-free survival, and overall survival over two to three years. Safety and treatment effects will be closely followed throughout the study duration, which lasts until 2031.
CONDITIONS
Brief Title
DEC003M in Prostate Cancer
Research Team
P
Pengyu Shi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here